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Abstract :

Synthetic inhibitors of the human mitogen activated protein kinase, p38 MAPK may
represent a new class of anti-parasitic agents. p38 MAPK inhibitors have been shown to
inhibit replication of Toxoplasma gondii (T.gondii), the causative agent of
taxoplasmosis, in vitro and in vivo. Inhibition of parasite replication was due to the
inhibition of a T.gondii p38 MAPK homolog called tgmapk-1. Other parasites have
MAPKs homologous to tgmapk-1 and these MAPKs may represent novel drug targets for
new therapeutics in treating parasitic diseases. We have focused on a MAPK from,
Leishmania mexicana (L.mexicana), the causative agent for one form of leishmaniasis.
The kinase, LmxMPKl, shares sequence homology to both human p38 MAPK and
tgmapk-1. It has been observed that a deletion mutation in the gene encoding LmxMPKl
renders the kinase inactive and the parasite unable to establish disease in a murine model
of this infection therefore, validating LmxMPKl as a potential parasite MAPK
therapeutic target. For my thesis research, I have expressed recombinant LmxMPKl in
mammalian HEK 293T cells and demonstrated basal kinase activity. A variety of kinase
inhibitors were evaluated for inhibition of LmxMPKl activity and one, the p38 MAPK
inhibitor, BIRB 796, was found to inhibit the enzyme. These results indicate that BIRB
796 may inhibit Leishmania replication through inhibition of LmxMPKl activity and
therefore represent a new anti-parasitic drug.
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Introduction
Leishmania
Leishmaniasis is a vector-borne disease that is transmitted by sandflies and
caused by an obligate intracellular protozoon of the genus Leishmania. Human infection
is caused by about 21 of 30 species that infect mammals. The different stages of
Leishmania life cycle are illustrated in figure 1. These include the L. donovani complex
with 3 species (L. donovani, L. infantum, and L.chagasi); the L.mexicana complex with 3
main species (.L.mexicana, L.amazonensis, and L.venezuelensis); L.tropica; L.major;
L.aethiopica; and the subgenus Viannia with 4 main species (L.(V.)braziliensis,
L.(V.)guyanensis, L.(V.)panamensis, and L.(V.)peruviana). The different species are
morphologically indistinguishable, but they can be differentiated by isoenzyme analysis,
molecular methods, or monoclonal antibodies. An estimated 350 million people live in
areas where the disease is endemic, of which 12 million in Africa, Asia, Europe and the
Americas are directly affected [1,2]. Leishmania is currently considered an emerging
infectious disease in parts of the world where it has become closely associated with
human immunodeficiency virus-acquired syndrome [3]. Leishmaniasis represents a
significant source of morbidity and mortality world-wide.
At present, the treatment of leishmaniasis relies primarily on chemotherapy
with pentavalent antimonials, which require long treatment periods and are often toxic [2,
3]. Unfortunately, therapy with antimonials can no longer be used in certain parts of the
world due to the emergence of drug resistance [4]. One rational approach in the hunt for
new anti-leishmanial drugs is to identify and target key intracellular signaling molecules
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that are vital to organism’s survival within the mammalian host. One such group of
signaling molecules appears to be protein kinases.
Protein kinases are class of enzymes responsible for many vital biochemical
processes such as, cell division, receptor cell signaling and apoptosis. The
phosphorylation of serine, threonine and tyrosine by various protein kinases is a process
that is amenable to selective targeting with small molecule drugs [5,6]. Targeting protein
kinases with small synthetic inhibitors has successfully led to the discovery of drugs such
as Gleevec, a Bcr/Abl kinase inhibitor, used to treat chronic myeleogenous leukemia
(CML) [7,8]. Recently it has been shown that a T.gondii parasite homolog of human p38
MAPK is important for parasite viability and can be targeted with known inhibitors [9].
The Mitogen Activated p38 Kinase ( p 38 MAPK ^Family
Mitogen-activated protein (MAP) kinases are a family of serine/threoninespecific protein kinases that mediate cellular responses to extracellular stress stimuli, cell
proliferation, differentiation and cell survival/apoptosis [10,11,12]. To date, 3 main
groups of MAPKs have been characterized in mammals, i.e. the extracellular signalregulated kinases (ERK1, ERK2 etc.), the c-Jun N-terminal Kinases/ stress activated
proteins (JNK/SAPK - MNPK8, MNPK9, MNPK10) and the p38 MAPK’s ( p38-a
(MAPK14), p (MAPK11), y (MAPK12) and 8 (MAPK13)) all of which share sequence
similarity and conserved structural domains. ERKs are activated by mitogens and growth
factors via a Ras dependent pathway [13, 14]. p38 and JNK are primarily responsive to
stress stimuli such as pro-inflammatory cytokines, lipopolysaccharides (LPS), ultraviolet
light, heat shock, osmotic shock and inhibitors of protein synthesis [15]. p38 MAP
Kinase, is the mammalian orthologue of the yeast HOG kinase, which functions in
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regulating osmotic stress responses [15,16,17]. Four p38 isoforms exist, p38-a
(MAPK14), -p (MAPK11), -y (MAPK12 or ERK6) and -6 (MAPK13 or SAPK4)
[16,17,18,19,20] which exhibit differences in tissue distribution, expression, substrate
specificity, regulation of kinase activation, subsequent phosphorylation of downstream
substrates and sensitivities toward p38 MAP kinase inhibitors [21,22,23]. The a and p
forms are expressed universally, y only in skeletal muscle and 5 is highly abundant in
testes, pancreas, kidney and small intestine. Differences in substrate specificity are also
known. Tau, a microtubule associated protein, is reported to be an efficient substrate for
p38y and 8, while MK2 and MK3 are known to be preferred substrates for p38a and
p38p. p38a is crucial to development since, loss of this form results in embryonic death
[24,25,26].
In response to cellular stresses, p38 MAPKs are activated by phosphorylation
of Thr180 and Tyr182 within a Thr-Gly-Tyr (TGY) motif located in a surface loop near the
active site of the enzyme. The loop is often referred to as the “phosphorylation lip” or
“activation lip” [27]. The upstream MAPK Kinase Kinases (MKK), MKK3 and MKK6,
are the primary activators for p38 MAPK. Once activated, p38 MAP kinase
phosphorylates and activates several substrates including MK2 and the transcription
factors ATF-2, Mac and MEF2 [17,28,29]. A simplified diagram of MAPK signaling
cascades is shown in figure 2
p38 MAPK inhibitors
Specific inhibitors of p38a/p MAPK have been designed to block the
production of inflammatory mediators in vitro and in vivo model systems. The pyridinyl
imadazole, SB-203580, was the first p38 MAPK inhibitor shown to be efficacious in
3

animal models of rheumatoid arthritis [30]. SB-203580 and other 2,4,5-triaryl imadazoles
bind to both active and inactive forms of the enzyme at the ATP binding site in a
competitive manner. The compound selectivity results from the binding of the imidazole
4-phenyl moiety to a hydrophobic pocket in the region containing Thr 106. The inhibitor,
BIRB 796, represents a unique class of p38 MAPK inhibitors that bind to an allosteric
site in the inactive form p38 MAPK as well as in the ATP binding site [30]. This class of
p38 MAPK inhibitors inhibits both the activation of p38 MAPK as well as its catalytic
activity while ATP competitive inhibitors inhibit only the catalytic activity of p38
MAPK. Representative p38 MAPK inhibitors are illustrated in figure 3. Several p38
MAPK inhibitors are presently in clinical trials as an oral treatment for rheumatoid
arthritis and other indications [30].
A Leishmania MAPK homolog required for Parasite viability
The T.gondii genome contains approximately 300 kinases, two of which,
tgmapk-1 & 2, are MAPK homologs [9]. It has been shown that inhibitors of human p38
MAP kinase inhibit tgmapk-1 kinase activity, block replication of the organism in
cultured human fibroblasts and protect mice against fatal T.gondii infection [31]. Other
parasites including Leishmania, express MAPK’s which may be required for parasite
viability as well and may be inhibited by known human p38 MAPK inhibitors.
The recent genome project of Leishmania has revealed the presence of
approximately 179 protein kinases in this organism [32]. Using the sequence of human
p38 MAPK and tgMAPK-2 kinases a Blast search of the Uniprot database revealed a

related MAPK in L. mexicana called, LmxMPKl. A clustal W comparision of human
p38, L.mexicana and T.gondii revealed significant sequence homology shown in figure 4.
Previously it has been shown that LmxMPKl is required for establishing
infection [32]. This was determined using a L.mexicana deletion mutant (Almsapl/2).
The mutant has a deletion region containing two Imsap genes (secreted acid phosphatase)
separated by an intrinsic region (6kb) that codes for LmxMPKl. This mutant L.mexicana
has lost its potential to develop lesions in Balb/c mice. Complementation experiments
provided the evidence that LmxMPKl region without Imsap genes was sufficient to
restore the proliferation and infection. These genetic data validate LmxMPKl as a drug
target since inhibition with a synthetic molecule may exhibit the same phenotype, i.e.
lack of infectivity [32]. The observations discussed above indicate the known p38
inhibitors may inhibit LmxMPKl and interfere with parasite viability.

Goals of study
My thesis research goals were to produce recombinant LmxMAPKl kinase by
expression in either bacterial or mammalian expression systems, biochemically
characterize the enzyme and determine susceptibility to a panel of known p38 inhibitors.
Successful inhibition of LmxMAPKl should allow further evaluation of the efficacy of
active inhibitors in appropriate cell culture and animal model systems.
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Materials and methods
pENTR 221 Vector Containing LmxMPKl
Full length recombinant LmxMPKl was generated synthetically (Blueheron
Technologies, Bothes W.A) from sequence obtained from the uniprot database
( www.uninrot.org, 000872) and cloned into the pENTR 221 vector (Gateway system,
Invitrogen). The pENTR 221 vector contains the LmxMPKl gene flanked between attLl
and attL2 recombination sites allowing for in vitro recombination in to a variety of
expression vectors. Gateway technology is a universal cloning method that provides a
rapid and highly efficient way to move a gene of interest into multiple destination vectors
(expression vectors) through site-specific recombination (Invitrogen Corp) [33].
A portion of the bacterial stab containing the LmxMPKl gene in the pENTR
221 vector was used to streak Lauria broth (LB) agar plates. LB plates were prepared by
dissolving LB and agar in distilled water and the media was autoclaved. After cooling,
the antibiotic kanamycin was added at a concentration of 50 pg/mL and the mixture
poured into 10 mm Petri dishes and allowed to solidify. Bacteria from the stab were
spread across the agar plate by discontinuous streaking. The plates were incubated
overnight at 37°C. A single well isolated colony was picked from the agar plate and
cultured overnight in 10 mL LB medium containing 50 pg/mL kanamycin. The following
day, pENTR 221 plasmid DNA was purified using a Promega pureyield plasmid mini
prep system according to the manufacturer’s instructions. In addition a glycerol stock was
made by using remaining overnight grown culture (3 mL). Bacteria were pelleted in LB
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media containing 15% glycerol and immediately placed in liquid nitrogen to freeze down
the cells. Cells were stored at -80°C for future use.
Creation of pDEST Gateway ®expression vectors & Hoechst DNA assay
The LmxMPKl gene was transferred into four Gateway® pDEST vectors using
In vitro recombination. pDEST 15 and pDEST 17 are bacterial expression vectors
producing N-terminal GST tagged and N-terminal His tagged proteins respectively. The
next two expression vectors, pDEST 26 and pDEST 27 are Gateway® mammalian
expression vectors which produce proteins containing N-terminal GST and N-terminal
His tags respectively.
pDEST vectors were obtained as super coiled plasmids from Invitrogen Life
Technologies. Each destination vector was supplied as 6 jug of plasmid. Plasmids were
resuspended in 40 pL of sterile water, vortexed and concentrations adjusted to 150
ng/pL. Vectors were propagated using One Shot ccdB survival T1Rchemically
competent E.coli cells (Invitrogen). The ccdB survival T1R£. coli strain transformed
with plasmids was resistant to ccdB effects and can supports the propagation of plasmids
containing ccdB gene. One shot ccdB survival competent cells were thawed on wet ice
and transformed with 1 pi containing 10 ng of each destination vector. Tubes were kept
on ice for 10 min and were subjected to heat shock treatment in a water bath at 42°C for
45-50 seconds. Tubes were placed on ice for 2 minutes and 300 pL of SOC media at
room temperature was added. The cultures were placed in an incubator for 60 min at
37°C with gentle shaking (200 rpm). After one hour incubation, the 50 pL of transformed
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bacterial cells were spread on LB agar plates containing 100 pg/mL ampicillin and 30
pg/mL chloramphenicol.
The LmxMPKl gene was transferred from pENTR 221 vector into the
destination vectors using an in vitro recombination reaction. The resulting reaction
mixture containing both pENTR 221 and pDEST vectors having the recombined
LmxMPKl gene was transformed into Library efficiency DH5a cells for the selection of
the appropriate expression clones. The following components were added to autoclaved
microcentrifuge tubes at room temperature for the recombination reaction: 100 ng/pL of
the pENTR vector and the 150 ng/pL of the appropriate destination vector were added
into the 7 pL of T.E buffer (10 mM tris HC1, pH 8.0, 1 mM EDTA). To each of the tubes
2 pL of LR clonase II enzyme mix (Invitrogen) was added and mixed well by pipetting
up and down. Reactions were incubated at 25°C for 2 hours. After incubation 1 pL of
proteinase K solution was added and the mixtures were incubated for 10 min at 37°C to
complete the recombination reaction. A negative control was set up by omitting the LR
clonase II enzyme mix.
In order to select for the expression clones, the recombination reaction mixture
was used to transform E.coli Library efficiency DH5a chemically competent cells as
previously described. Transformed cells were spread on pre warmed LB plates containing
100 pg/mL ampicillin and incubated overnight at 37°C. The following day, 2-3 well
isolated colonies were picked up from each agar plate and cultured overnight in 50 mL
LB medium containing 100 pg/mL ampicillin. The cultures were grown at 37°C
incubator with vigorous shaking until they reached the biomass between 100-200 (O.D
600 of culture xVolume of culture). Plasmid DNA was prepared using the Promega pure
8

yield plasmid midi prep system. Plasmid DNA was quantified by using a modified
Hoechst DNA assay [1]. The Hoechst 33258 dye [Sigma] was diluted to 20 pg/mL in
TNE buffer [lOmM Tris pH-7.5, 200 mM Nacl and 1 mM EDTA]. Reference DNA was
calf thymus DNA [Sigma]. Equal volumes of DNA and dye were added to each well and
fluorescence was measured at an excitation at 360 nm and emission at 460 nm. The assay
was linear from 10-400 ng/mL as shown in figure 5.
True expression clones were ampicillin resistant and chloramphenicol sensitive.
The non transformants are not competent to grow in Library efficiency DH5a cells. In
order to check the putative expression clone, the growth was checked on LB agar plates
containing 30 pg/mL chloramphenicol. A true expression clone will not grow in the
presence of chloramphenicol.
Expression of LmxMAPKl
We were not successful in expressing LmxMAPKl in bacteria. So,we switched
our focus to expression in mammalian cells. We used Human embryonic kidney cells
(HEK 293T). The HEK 293T cell line (ATCC number # CRL 11268) is a highly
transferable derivative of the 293 cell line in to which the temperature sensitive gene for
SV40 T- antigen was inserted. These cells constitutively express the simian virus 40
(SV40) large T antigens, and clone 17 was selected specifically for its high
transfectability. The cells were propagated in 10% Dulbecco’s modified eagles medium
with 4 mM glutamine and 1% Penstrep. Fetal bovine serum was added to the base
medium to make complete growth medium. The cells were sub cultured for every 2 to 3
days at a ratio of 1:4 to 1:8 depending on the growth of the cells.
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The day before transfection culture media was aspirated and cells were treated
with 0.25% trypsin for 7 min to detach the cells. Then 10 mL of complete growth
medium having no antibiotics was added. Cells were counted using a hemocytameter.
Approximately 5><106 cells were plated for each T75 cm2 culture flask in 25 mL of
complete growth medium. On the day of transfection the media was replaced with 25 mL
of complete growth medium having no antibiotics. Cell density was approximately 80%
confluent.
We followed a transfection protocol obtained from Dr. Ray Birge (UMDNJ, NJ
unpublished protocol) in order to express the GST and His tagged LmxMPKl in Human
embryonic Kidney cells (HEK 293T). For each T75 cm2 culture flask 7.5 pg of pDEST
DNA was used for transfection. A master Mix was made by adding 7.5 pL of
Lipofectamine 2000 reagent (Invitrogen) to 950 pL of Opti-MEM® reduced serum
medium per sample and allowed to stand for 5 minutes. 7.5 pg of DNA was diluted in 2
mL Opti-MEM® (Invitrogen) and to this added 950 pL of above Lipofectamine 2000/
Opti-MEM mixture for each plasmid. Mixtures were allowed to stand for 15 minutes
and 7.5 mL of Opti-MEM® was added to the solution. Cells were washed once with OptiMEM . This mixture was poured on to cells and after 4 hours, 15 mL of complete growth
media (with antibiotics) was added. Cells were placed in the incubator. The next day
media was changed with complete growth medium. The cells were harvested after 48
hours under cold conditions. Cells were lysed using M-PER mammalian protein
extraction reagent (Pierce) containing protease inhibitors (Halt protease Inhibitor single
use EDTA free cocktail, Pierce). Each flask was gently agitated in the cold for 5-10 min
and cell lysate prepared by centrifugation at 14000x g for 10 minutes at 4°C.
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Supernatants were transferred to a tube for protein analysis and the cell pellet was stored
at -20°C.
For high level recombinant protein production we used the Free Style 293 F
cell system (Invitrogen). The Free Style Expression system is a proprietary system that
utilizes HEK 293T cells adapted to grow in suspension under protein free conditions. The
maintenance of the cell line as well as transfection followed the manufacture
recommended protocol (Invitrogen). The suspension cells were grown in an incubator at
37°C, 8% CO2 and kept in suspension using an orbital shaker. Cell lysates were prepared by
spinning down cells at lOOxg for 5 min in a cold centrifuge. Cells were washed with 10
mL of ice-cold PBS and again spun down at lOOxg for 5 min in a cold centrifuge. Cells
were lysed with 2 mL of ice-cold lysis buffer and allowed to incubate on ice for 15 min.
The following cell lysis buffers were used for GST-tagged protein purification: 10 mM
Hepes, pH 7.4, 50 mM p-glycerolphosphate, 1% Triton X-100, 10% Glycerol, 2 mM
EDTA, 2 mM EGTA, 1 mM DTT, 10 mM NaF and HALTS protease cocktail (100X).
For His tagged protein purification the buffer was 10 mM Hepes, pH 7.4, 50 mM Pglycerolphosphate, 1% Triton X-100, 10% glycerol, 10 mM NaF and HALTS protease
cocktail (100X). Following lysis cells were centrifuged at 14000xg for 10 min at 2-4°C to
pellet nuclei. Supernatant was stored in ice.
Purification of GST and His tagged LmxMAPKl
For purification of GST-tagged LmxMPKl a B-PER GST spin purification Kit
containing immobilized glutathione column was used (Pierce). For the purification of
His tagged recombinant proteins, His Pur Purification Kit containing HisPur Cobalt Spin
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Column was used (Pierce). Protein concentration was determined by using Bradford
protein assay (Biorad). Standard reference protein Bovine serum albumin (BSA) was
made up to 1 mg/mL in Phosphate buffer saline (PBS). Total assay volume was 200 pL
and absorbance was measured at 592 nm. The assay was linear from 80 pg to 0.8 pg as
shown in figure 6.
SPS-PAGE analysis and Western blotting of GST- LmxMPKl protein
Protein fractions were analyzed using Sodium Dodecyl Sulfate Polyacrylamide
Gel Electrophoresis (SDS-PAGE). For the SDS-PAGE, a 10 well 4-12% Bis-Tris gel
NuPAGE Novex (Invitrogen) was used. The gel was run using MOPS SDS running
buffer. Samples (10 pL) were prepared in NuPAGE SDS sample buffer (4X) with
NuPAGE Reducing agent (10X) and heated at 70°C for 10 min. 10 pL of Novex protein
standards were used as a control. The gel was run at 200 V constant for 50 min. Two
gels were routinely run; one for western blot analysis and the other for staining with
Coomassie Brilliant Blue. The stain was made with 0.1% Coomassie Brilliant Blue
(0.025 g), 40% methanol (10 mL), 1% acetic acid (250 pL) and then filled with distilled
water to a final volume of 25 mL. After the three hour stain, a destainer containing 50%
methanol (15 mL) was added to the gel and left overnight. The banding pattern of the gel
was then analyzed.
For Western Blotting an X Cell Sure Lock Mini cell blotting module
(Invitrogen) was used for gel transfer. Blotting was done in the cold room at 30 V for 1.5
h. The PVDF membrane was developed using a chromogenic detection kit (Western
Breeze). The membranes were blocked with 10 mL blocking solution for 30 minutes and
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rinsed twice with distilled water. Then incubated with 1:1000 dilutions, Goat Anti-GST
primary antibody solution for one hour and washed three times with provided antibody
wash (IX). The membrane was then incubated with rabbit Anti-Goat HRP conjugated
IgG secondary antibody (1:6000) for 30 minutes and washed 3 times with antibody wash
solution. The membrane was rinsed with water and developed by TMB stabilized
substrate for horse raddish peroxidase (HRP).
LmxMPKl Kinase Activity Determination
Recombinant LmxMPKl activity was determined by 33P incorporation into
myelin basic protein (MBP) using [y 33P] labelled ATP. The enzyme was incubated with
myelin basic protein (MBP) and ATP in the presence and absence of 1 pM kinase
inhibitors. Reaction conditions were: 62.5 mM HEPES, pH 7.5, 62.5 mM pglycerophosphate, 25 mM MgCl2, 2.5 mM DTT, 50 pM ATP, 2 pci of [y 33P] ATP in the
presence and absence of 1 pM inhibitor. Inhibitors evaluated were RWJ67657, BIRB 796
and Staurosporine.
Reactions were incubated at 37°C for 25 min and stopped with addition of SDS
sample buffer. Reaction mixtures (10 pL) were subjected to SDS-PAGE and
autoradiography. Each sample was loaded on a 4-12% PAGE gel and electrophoresed
for 60 min at 200 V constant. The gel was stained with simple blue (sigma) and dried on
to filterpaper using an Ephortec Gel Dryer. The dried gel was exposed to KODAK
BioMax Light Film for 4 hours and the film was developed. The autoradiogram was
scanned for phosphorylated MBP using the ImageJ program (version 1.41, Rasband,
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NIH). From the area under the curves (AUC) the pixel intensity for each of the bands
were determined. Each lane was scanned a minimum of 3 times.

Results
LmxMPKl expression and purification
The decision was made to use the Gateway cloning system (Invitrogen) to
produce appropriate expression vectors. This system has the advantage of shuttling a
gene efficiently between various expression vectors using in vitro recombination [33].
Two bacterial expression vectors were generated from the pENTR 221 vector containing
the synthetic LmxMPKl gene. pDEST15-LEISH & pDEST17-LEISH are designed to
express N-terminal 6xHis-tagged and GST tagged LmxMPKl. Two mammalian
expression vectors were similarly generated to express N-terminal GST and N-terminal
6xHis-tagged LmxMPKl.
pDEST expression vectors were maintained and purified as described in
methods. I obtained the following yields of the plasmids: pDEST15, 111.0 pg/mL,
pDEST17, 44.0 pg/mL, pDEST26, 77.0 pg/mL and pDEST27, 134.0 pg/mL [Table 1].
In vitro recombination between the pENTR 221-LEISH vector and each pDEST
expression vector (methods) yielded the following pDEST-LEISH vector concentrations:
pDESTl 5-LEISH, 74 pg/mL, pDEST 17-LEISH, 41.0 pg/mL, pDEST26-LEISH, 181.0
pg/mL and pDEST27-LEISH, 401.0 pg/mL [Table 2], Plasmid yields were similar to the
yields provided by the Promega manual.
E.coli BL 21 A1 bacteria and human HEK 293T cells were transfected as
outlined in the materials section. Preliminary studies failed to show any expression of
14

6xHis or GST-LmxMPKl in bacteria or expression of 6xHis in HEK 293T cells, however
expression of GST-LmxMPKl was observed in HEK 293T cells. In view of these results,
I only focused my efforts on GST-LmxMPKl production in HEK 293T cells.
HEK 293T cells were transfected with the pDEST27-LEISH vector as described
in the methods section. After 48 hours, one T75 cm flask was immediately harvested and
the second treated with 400 pM sodium arsenate for 4 hours prior to harvesting the cells.
Sodium arsenate has been shown to stress the HEK 293T cells and activate the p38
MAPK pathway [36]. It was hoped that this would lead to activation of LmxMPKl. Cells
were lysed and GST-LmxMPKl was purified using glutathione-immobilized beads as
described in methods. SDS PAGE and Western blotting analysis of various fractions
from the purification procedure revealed expression of GST-LmxMPKl and selective
purification of LmxMPKl from the glutathione affinity resin [Figure 7 & 8]. The analysis
indicated a molecular weight of 67 kDa for GST- LmxMPKl which agrees with the
predicted molecular weight for LmxMPKl of 41 kDa plus the GST epitope molecular
weight of 26 kDa.
Evaluation of LmxMPKl catalytic activity
The catalytic activity of the purified recombinant LmxMPKl enzyme was
determined using an in vitro kinase assay (methods). LmxMPKl phosphorylated the
commonly used MAP kinase (MAPK) substrate, myelin basic protein (MBP). As shown
in figure 9, LmxMPKl exhibited much less activity compared to activated human p38
kinase in the in vitro kinase assay. Attempts to activate LmxMPKl by stressing with

15

arsenate failed. This result indicates a different mode of LmxMPKl activation than for
p38.
The effects of human p38 MAPK inhibitors on LmxMPKl basal activity
Three protein kinase inhibitors were evaluated for the inhibition of LmxMPKl
basal activity. BIRB 796, an allosteric p38 inhibitor binds to a novel allosteric site on
human p38MAPK was effective in inhibiting basal level LmxMPKl activity [figure 9].
RWJ67657, an ATP competitive inhibitor was with out effect (data not shown).
Staurosporine a non selective protein kinase inhibitor with poor activity against MAP
kinases gave slight inhibition.

Discussion
I have shown that a small synthetic inhibitor of the human mitogen activated
protein kinase (MAPK), specifically p38 MAPK (p38), inhibits the activity of a
leishmania MAPK kinase (LmxMPKl).
As discussed in the introduction, L.mexicana Almsapl/2 deletion mutant
results in the inactivation of LmxMPKl, resulting in the parasite unable to establish
progressive disease in a Balb/c mouse model [32]. Further more, the parasite Toxoplasma
gondii (T.gondii), expresses a protein kinase tgmapk-1 that shares significant homology
with L.mexicana LmxMPKl. Since tgmapk-1 activity can be inhibited by the
pyridinylimidazole class of p38 inhibitors and these inhibitors inhibit T.gondii replication
in cultured human fibroblast cultures [34], we argued that inhibiting LmxMPKl activity
with synthetic p38 inhibitors may be possible.
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Using the Gateway cloning and expression system, we successfully expressed
LmxMPKl in human HEK 293T cells. LmxMPKl exhibited low but measurable protein
kinase activity using MBP as substrate. Attempts to produce fully active LmxMPKl by
activating HEK 293T cell with arsenate failed. This indicates that the LmxMPKl kinase
activation domain requires specific Leishmania upstream kinases. This is not surprising
since the kinase activation motif for LmxMPKl is TDY while that for p38 is TGY.
Future experiments will be required for expression of relevant upstream kinases that have
recently been identified through genome sequencing [35].
Three distinct classes of protein kinase inhibitors were evaluated for inhibitory
activity. First, the diaryl urea based p38 inhibitor; BIRB 796 having a novel mode of
action by binding to an allosteric site was evaluated. Second, RWJ67657 an N-substituted
pyridinylimadazole p38 inhibitor, which was synthesized at Montclair state university in
a collaborative effort between Dr. Siekierka and Dr. Fina Liotta’s laboratories is an ATP
competitive inhibitor of human p38MAPK and is active against Igondii tgmapk-1.
Thirdly, we evaluated staurosporine, a non-selective general protein kinase inhibitor
known to have poor activity against MAPKs. BIRB 796 inhibited LmxMPKl activity by
47%. We were unable to demonstrate effective inhibition with p38 inhibitor RWJ 67657
(data was not shown). Staurosporine exhibited minimal inhibition of 17%. This confirms
that LmxMPKl is a member of the MAPK family, since MAPK’s are poorly inhibited by
staurosporine.
BIRB 796 has a different mode of action than the traditional
pyridinylimidazole-based p38 inhibitors such as SB 20350 and RWJ 67657. The
pyridinylimidazole p38 inhibitors bind to the ATP binding pocket. BIRB 796 binds to an
17

allosteric site called the DFG region on all p38 MAPK’s as well as partially in to the ATP
binding site. BIRB 796 inhibits all four human p38 isoforms, but RWJ67657 inhibit only
p38 a and (3 isoforms. The fact that BIRB 796 shows inhibitory activity against
LmxMPKl, and that RWJ 67657 is inactive illustrates the importance of key interactions
between inhibitors and protein kinases. Clearly these experiments will require
confirmation with fully activated LmxMPKl kinase.
In addition, further optimization of LmxMPKl expression is required to
produce higher protein yields. This was addressed by utilizing the Free Style 293 F cell
system (Invitrogen). This system utilizes a special suspension culture with the HEK 293T
cells. In preliminary experiments with this system (data not shown), we successfully
obtained a yield of 266 pg of LmxMPKl protein. This will allow further manipulation of
LmxMPKl.
Regarding the activation issue, there are two possible ways of generating the
fully active kinase, other than using the isolated physiological upstream leishmania
kinases. The first way is to mutate the leishmania kinase activation domain TDY to
human p38 activation domain TGY. This may potentially allow recognition by
mammalian upstream p38 activators such as MKK6 or MKK3 under stress conditions.
Secondly, it has been shown in other systems that introduction of a negatively charged
glutamate (E) residue instead of the threonine residue in the TDY motif of LmxMPKl
can mimic phosphorylated threonine generating a constitutively activated kinase [36].
In summary I have successfully expressed the LmxMPKl kinase in human HEK
293T cells. I have also shown the BIRB 796 class of p38 MAPK inhibitors can inhibit the

18

basal LmxMPKl kinase activity. These results hold promise for inhibiting LmxMPKl in
the parasite. Further characterization of this inhibitory activity is needed along with the
evaluation of BIRB 796 in in vitro and in vivo models of leishmania infection.
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Figure 1: Different stages of Leishmania lifecycle in both sandfly and humanbeings
Taken from fhttp://www.dpd.cdc.gov/DPDx/HTML/Leishmaniasis.htm1 Leishmaniasis is
transmitted by the bite of infected female phlebotomine sandflies. The sandflies inject the
infective stage (i.e., promastigotes) from their proboscis during blood meals 0. Promastigotes
that reach the puncture wound are phagocytized by macrophages 0 a nd other types of
mononuclear phagocytic cells. Progmastigotes transform in these cells into the tissue stage of
the parasite (i.e., amastigotes) 0, which multiply by simple division and proceed to infect other
mononuclear phagocytic cells 0. Parasite, host, and other factors affect whether the infection
becomes symptomatic and whether cutaneous or visceral leishmaniasis results. Sandflies
become infected by ingesting infected cells during blood meals

(

00
,

).

In sandflies,

amastigotes transform into promastigotes, develop in the gut 0 (in the hindgut for leishmanial
organisms in the Vionnia subgenus; in the midgut for organisms in the Leishmania subgenus),
and migrate to the proboscis
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Figure 2: Simple illustration of p38 signaling cascade

A) Pyrinidylimadazole based p38 kinase inhibitor, SB 203580

RVUU 67657

B) Structure of N-substituted Pyrinidylimadazole based p38 inhibitor, RWJ 67657

C) Structure of the diaryl urea based p38 MAP kinase inhibitor, BIRB 796
Figure 3: Structures of p38 kinase inhibitors
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DNA (ng/mL)

Figure 5: Standard curve for Hoechst DNA Assay

24

DNA Concentration
(Hg/mL)

Volume
(HL)

pENTR-LEISH

433

30

Total Amount Of
DNA
G*g)
12.98

pDEST 26

77

60

4.62

pDEST 27

134

30

4.01

pDEST 15

111

30

3.34

pDEST 17

44

55

2.45

pDEST 26 (His tagged), pDEST 27 (GST tagged) are mammalian destination
vectors.
pDEST 15 (GST tagged), pDEST 17 (His tagged) are bacterial destination vectors.

Table 1: DNA concentrations of pENTR-LEISH and Destination vectors.
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DNA Concentration
(Hg/mL)
pDEST26 -

Volume
OiL)

Total Amount Of
DNA
(l*g)
181.1

181

1000

401

1000

401.1

74

60

4.5

41

60

2.5

LEISH
pDEST27 LEISH
pDEST 15 LEISH
pDEST 17 LEISH

Table 2: DNA Concentrations of bacterial and mammalian expression vectors by
Hoechst DNA assay
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y =03241x+0.0129
R2=0.9801

♦ Standard Data Points
--- Linear (Standard Data
Points)

Concentration of Protein (mg/mL)

Figure 6: Standard curve for Bradford Assay
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Sample

Unstimulated
Stimulated

Crude
Extract
(pg/mL)
2273
2603

Flow Through
(pg/mL)

Washes
(pg/mL)

Elutions
(pg/mL)

2610

172

Nd

2949

164

Nd

Concentrations in elution samples were less than the sensitivity of Bradford Assay
[Nd- not detected].
Table 3: Protein concentrations of GST - LmxMPK 1 from HEK 293 T (Monolayer)
cells by Bradford Assay
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Western blot of GST-LmxMPKl with anti-GST. Lane 1) Protein MW markers, 2)
Control, non-transfected crude extracted HEK 293T cells, 3) Crude extract from
LmxMPKl-transfected HEK 293T cells, 4) Column flow through, 5) Column wash
fraction 6) Glutathione (10 mM) eluted GST-LmxMPKl fraction, 7&8) Detergent treated
glutathione sepharose beads 9) GST-p38 standard, and 10) MW IgG markers
Figure 7: Western blot of GST-LmxMPKl with anti-GST
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Lane 1) Molecular weight markers 2) Positive control- GST p38 3) GST-LmxMPKl
crude extract 4) GST-LmxMPKl Flow through 5) GST-LmxMPKl Eluent I 6) GSTLmxMPKl Eluent II 7) Negative control- crude extract 8) Negative control Flow through
9) Negative control Eluent 110) Negative control Eluent II
Figure 8: Comassine Brilliant blue stained SDS - PAGE gel
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-

1

2

3

Jj|>

5

6

7

8

C)

Lane#
1
2
3
4
5
6
7
8

Sample
No enzyme + MBP
LmxMPKl (no treatment)
LmxMPKl + arsenite treatment (a)
LmxMPKl (a) + BIRB 796
LmxMPKl (a) + staurosporine
p38 (a)
p38 (a) + BIRB 796
p38 (a) + staurosporine

Mean ±
33
4,226
5,957
3,180
4,932
11,389
3,508
10,354

SD
14
102
144
683
882
711
390
634

% Inhibition
n/a
29
0
47
17
0
69
9

P value
<0.001
<0.001
0.036
<0.001
0.103

p value was obtained by an unpaired two sided t-test. The reference values were
LmxMAPKl and p38. A p value of <0.01 was considered significant (*).

A) Auto radiogram B) Histogram of the area under the curve for each lane C) Table
showing the values of each lane.
Figure 9: Leish mania LmxMPKl Kinase Assay with BIRB 796 and
staurosporine Inhibitors.
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